Second-quarter earnings disappointments, recent clinical trial failures and investors' apparent refusal to credit any of the good news have pushed biotechnology valuations down to levels not seen since the mid-1990s. (BioWorld Financial Watch)

Hardly had the House passed the Prescription Drug User Fee Act - clearing the way for the next day's approval by the Senate - than all eyes turned from PDUFA to Amevive, Biogen Inc.'s fusion protein for psoriasis. (BioWorld Financial Watch)

Although the American Society of Clinical Oncology meeting in Orlando, Fla., which wrapped up last week, spewed much data and generated plenty of talk, the news wasn't all good for biotechnology firms, nor was it all bad. In a down market, however, the word "mixed" doesn't carry quite the cautious optimism it once did at least not for those with cash on the line. (BioWorld Financial Watch)